drugset / Trial / NCT03458481
Phase 2 Study of Yimitasvir Phosphate Capsules
RandomizedParallel-groupOpen-labelTreatment
Summary
The safety, tolerability and antiviral activity of DAG181/SOF in treatment-naive and treatment-experienced patients with chronic hepatitis C virus (HCV) genotype 1 infection
Timeline
- Start
- 2017-07-31
- Primary completion
- 2018-05-08
- Completion
- 2018-09-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Yimitasvir | Small molecule | 100 mg | Oral |
| Subject | Yimitasvir | Small molecule | 200 mg | Oral |
| Background | SOF | Unknown | 400 mg | Oral |